» Articles » PMID: 2695102

CD44--a Molecule Involved in Leukocyte Adherence and T-cell Activation

Overview
Journal Immunol Today
Date 1989 Dec 1
PMID 2695102
Citations 122
Authors
Affiliations
Soon will be listed here.
Abstract

The study of cell surface molecules that are involved in interactions between immune and non-hematopoietic cells in various microenvironments is currently an area of great interest. One molecule that appears to be involved in multiple steps of normal immune cell function is now called CD44 and has been known previously as Pgp-1, In(Lu)-related p80, Hermes, ECM-III and HUTCH-I. Within the past year, the co-identity of all of these independently discovered molecules has become apparent, and the role of the CD44 molecule in T-cell activation has been discovered. In this review, Barton Haynes and his colleagues bring together numerous divergent lines of investigation on the CD44 molecule, review the many functional roles attributed to it, and present a unifying view of how, with numerous ligands, it may participate in several areas of normal immune cell function.

Citing Articles

Circulating tumor cells: from new biological insights to clinical practice.

Gu X, Wei S, Lv X Signal Transduct Target Ther. 2024; 9(1):226.

PMID: 39218931 PMC: 11366768. DOI: 10.1038/s41392-024-01938-6.


Immune suppressive drugs negatively regulate the CD8T cells function by acetyltransferase p300 induced canonical and non-canonical autophagy.

Ni R, Fan L, Wang H, Zhang Q, Zhang L, Wang A Heliyon. 2024; 10(13):e33755.

PMID: 39071589 PMC: 11283165. DOI: 10.1016/j.heliyon.2024.e33755.


ABO Blood Group and the Risk and Prognosis of Lymphoma.

Qin L, Gao D, Wang Q, Zheng X, Wang J, Chen X J Inflamm Res. 2023; 16:769-778.

PMID: 36855543 PMC: 9968433. DOI: 10.2147/JIR.S401818.


Identification of Chicken CD44 as a Novel B Lymphocyte Receptor for Infectious Bursal Disease Virus.

Liu A, Pan Q, Wang S, Zhang Y, Li Y, Wang Y J Virol. 2022; 96(6):e0011322.

PMID: 35107370 PMC: 8941901. DOI: 10.1128/jvi.00113-22.


Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer.

You K, Yi Y, Cho J, Park J, Seong Y Pharmaceuticals (Basel). 2021; 14(6).

PMID: 34207383 PMC: 8233743. DOI: 10.3390/ph14060589.